+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Global Canine Atopic Dermatitis Market by Product (Antihistamines, Glucocorticoids, Immunosuppressants), Allergen (Dander, Microorganisms, Mites), Route of Administration, Distribution Channel, End-User - Forecast 2024-2030

  • PDF Icon

    Report

  • 181 Pages
  • March 2024
  • Region: Global
  • 360iResearch™
  • ID: 5337468
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Canine Atopic Dermatitis Market size was estimated at USD 1.57 billion in 2023, USD 1.69 billion in 2024, and is expected to grow at a CAGR of 8.40% to reach USD 2.76 billion by 2030.

Canine atopic dermatitis (CAD) is a chronic, pruritic inflammatory skin condition in dogs due to an inherited predisposition to aberrant immune responses and environmental allergens. Increasing dog ownership rates with changing lifestyles and greater awareness about pet healthcare have led to the adoption of CAD treatments worldwide. Recent years have observed advancements in diagnostic techniques, enabling effective treatment solutions for this chronic condition. However, high costs associated with diagnostics and long-term management can also be a barrier for pet owners, limiting the adoption of new treatments and therapies. Regulatory hurdles can impede the development and approval of novel therapeutics in the canine atopic dermatitis market. Companies are working on innovative research to offer cost-effective treatments while ensuring knowledge of the changing regulations to ensure the commercialization of diverse CAD treatments. Emerging technologies such as next-generation sequencing (NGS) could help identify genetic factors contributing to canine atopic dermatitis susceptibility or treatment response, providing valuable information for personalized therapy approaches.

Regional Insights

The Americas CAD market is advancing, driven by huge developments in veterinary medicine and ongoing research activities by established companies to offer new-generation treatments. With an increasing number of pet owners becoming aware of CAD's impact on their pets' quality of life in the U.S. and Canada, demand for effective treatments has surged in the region. The prevalence of CAD is significantly rising across Asian countries, particularly in urbanized regions. However, limited awareness about veterinary dermatology and fragmented market structures present challenges to companies catering to this region. Major global players have established a presence in Asia; however they need to contend with smaller local manufacturers that offer cost-effective alternatives for CAD treatments. The European market presents a mature landscape for veterinary dermatology, characterized by well-established companies offering specialized diagnostic tools and therapeutic solutions for managing CAD. Partnerships between leading pharmaceutical firms have led to the development of innovative monoclonal antibody therapies, which offer targeted relief from pruritus associated with atopic dermatitis.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Canine Atopic Dermatitis Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Canine Atopic Dermatitis Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Canine Atopic Dermatitis Market, highlighting leading vendors and their innovative profiles. These include AB Science SA, AbbVie, Inc., Agrolabo SpA, Bimeda, Inc., Bioceltix JSC, Bioiberica S.A.U., Boehringer Ingelheim International GmbH, Ceva Santé Animale, Dechra Pharmaceuticals PLC, Deep Marine Collagen, Elanco Animal Health Incorporated, Farnam Companies, Inc., IDEXX Laboratories, Inc., Incyte Corporation, Kemin Industries, Inc., LEO Pharma A/S, Merck & Co. Inc., Natural Dog Company, Nextmune, Nippon Zenyaku Kogyo Co., Ltd., Novartis AG, Ourofino Animal Health, Pfizer Inc, Phibro Animal Health Corporation, Regeneron Pharmaceuticals, Inc, Saiba Animal Health AG, Toray Industries Inc., Vetoquinol S.A., Virbac Corporation, Zinpro Corporation, Zoetis Inc., and Zymox by Pet King Brands LLC.

Market Segmentation & Coverage

This research report categorizes the Canine Atopic Dermatitis Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Product
    • Antihistamines
    • Glucocorticoids
    • Immunosuppressants
    • Monoclonal Antibodies
  • Allergen
    • Dander
    • Microorganisms
    • Mites
    • Pollen
  • Route of Administration
    • Injectable
    • Oral
    • Topical
  • Distribution Channel
    • Hospitals & Clinics
    • Online
    • Retail Veterinary
  • End-User
    • Hospitals
    • Veternary Clinics
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects

  1. Market Penetration: It presents comprehensive information on the market provided by key players.
  2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
  3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
  4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
  5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as

  1. What is the market size and forecast of the Canine Atopic Dermatitis Market?
  2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Canine Atopic Dermatitis Market?
  3. What are the technology trends and regulatory frameworks in the Canine Atopic Dermatitis Market?
  4. What is the market share of the leading vendors in the Canine Atopic Dermatitis Market?
  5. Which modes and strategic moves are suitable for entering the Canine Atopic Dermatitis Market?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Canine Atopic Dermatitis Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing number of pet ownership and rising pollution related to allergens on dogs
5.1.1.2. Rising focus on natural ingredients or non-pharmacological methods
5.1.2. Restraints
5.1.2.1. Increasing use of off-label drugs among pets
5.1.3. Opportunities
5.1.3.1. Rise in the R&D investments product launches for canine atopic dermatitis (CAD)
5.1.3.2. Ongoing demand for pet insurance and rising concerns among pet owners
5.1.4. Challenges
5.1.4.1. Complex etiology of CAD & concerns over treatment efficacy and safety
5.2. Market Segmentation Analysis
5.2.1. Product: Expanding use of antihistamines and glucocorticoids for effective treatment of CAD
5.2.2. Allergen: Dust mites and microscopic parasites prevail as the major cause of CAD
5.2.3. Route of Administration: Injectables and orals to be the most preferred mode of medication application
5.2.4. Distribution Channel: Emerging availability of CAD medications through online distribution channels
5.2.5. End-User: Increasing CAD diagnosis in clinics and need for effective treatments
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Canine Atopic Dermatitis Market, by Product
6.1. Introduction
6.2. Antihistamines
6.3. Glucocorticoids
6.4. Immunosuppressants
6.5. Monoclonal Antibodies
7. Canine Atopic Dermatitis Market, by Allergen
7.1. Introduction
7.2. Dander
7.3. Microorganisms
7.4. Mites
7.5. Pollen
8. Canine Atopic Dermatitis Market, by Route of Administration
8.1. Introduction
8.2. Injectable
8.3. Oral
8.4. Topical
9. Canine Atopic Dermatitis Market, by Distribution Channel
9.1. Introduction
9.2. Hospitals & Clinics
9.3. Online
9.4. Retail Veterinary
10. Canine Atopic Dermatitis Market, by End-User
10.1. Introduction
10.2. Hospitals
10.3. Veternary Clinics
11. Americas Canine Atopic Dermatitis Market
11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States
12. Asia-Pacific Canine Atopic Dermatitis Market
12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam
13. Europe, Middle East & Africa Canine Atopic Dermatitis Market
13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom
14. Competitive Landscape
14.1. FPNV Positioning Matrix
14.2. Market Share Analysis, By Key Player
14.3. Competitive Scenario Analysis, By Key Player
14.3.1. Agreement, Collaboration, & Partnership
14.3.1.1. ILC Therapeutics entered into a strategic R&D partnership with Dechra Pharmaceuticals
14.3.2. New Product Launch & Enhancement
14.3.2.1. Bioiberica Launches Dog And Cat Collar For Atopic Dermatitis Featuring Company’s Lipids-Based Biosfeen Ingredient
14.3.2.2. Royal Canin North America Announces Launch of SKINTOPIC to Help in the Management of Canine Atopic Dermatitis
14.3.3. Award, Recognition, & Expansion
14.3.3.1. Zoetis Opens New State-of-the-Art Facility in Lincoln, NE, USA
14.3.3.2. Zoetis Announces FDA Approval of Apoquel Chewable (oclacitinib chewable tablet) for Control of Pruritus Associated With Allergic Dermatitis and Control of Atopic Dermatitis in Dogs
15. Competitive Portfolio
15.1. Key Company Profiles
15.1.1. AB Science SA
15.1.2. AbbVie, Inc.
15.1.3. Agrolabo SpA
15.1.4. Bimeda, Inc.
15.1.5. Bioceltix JSC
15.1.6. Bioiberica S.A.U.
15.1.7. Boehringer Ingelheim International GmbH
15.1.8. Ceva Santé Animale
15.1.9. Dechra Pharmaceuticals PLC
15.1.10. Deep Marine Collagen
15.1.11. Elanco Animal Health Incorporated
15.1.12. Farnam Companies, Inc.
15.1.13. IDEXX Laboratories, Inc.
15.1.14. Incyte Corporation
15.1.15. Kemin Industries, Inc.
15.1.16. LEO Pharma A/S
15.1.17. Merck & Co. Inc.
15.1.18. Natural Dog Company
15.1.19. Nextmune
15.1.20. Nippon Zenyaku Kogyo Co., Ltd.
15.1.21. Novartis AG
15.1.22. Ourofino Animal Health
15.1.23. Pfizer Inc
15.1.24. Phibro Animal Health Corporation
15.1.25. Regeneron Pharmaceuticals, Inc
15.1.26. Saiba Animal Health AG
15.1.27. Toray Industries Inc.
15.1.28. Vetoquinol S.A.
15.1.29. Virbac Corporation
15.1.30. Zinpro Corporation
15.1.31. Zoetis Inc.
15.1.32. Zymox by Pet King Brands LLC
15.2. Key Product Portfolio
16. Appendix
16.1. Discussion Guide
16.2. License & Pricing
List of Figures
FIGURE 1. CANINE ATOPIC DERMATITIS MARKET RESEARCH PROCESS
FIGURE 2. CANINE ATOPIC DERMATITIS MARKET SIZE, 2023 VS 2030
FIGURE 3. CANINE ATOPIC DERMATITIS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. CANINE ATOPIC DERMATITIS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. CANINE ATOPIC DERMATITIS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. CANINE ATOPIC DERMATITIS MARKET DYNAMICS
FIGURE 7. CANINE ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
FIGURE 8. CANINE ATOPIC DERMATITIS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. CANINE ATOPIC DERMATITIS MARKET SIZE, BY ALLERGEN, 2023 VS 2030 (%)
FIGURE 10. CANINE ATOPIC DERMATITIS MARKET SIZE, BY ALLERGEN, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. CANINE ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 12. CANINE ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. CANINE ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
FIGURE 14. CANINE ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. CANINE ATOPIC DERMATITIS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 16. CANINE ATOPIC DERMATITIS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS CANINE ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. AMERICAS CANINE ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES CANINE ATOPIC DERMATITIS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 20. UNITED STATES CANINE ATOPIC DERMATITIS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC CANINE ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC CANINE ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA CANINE ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 25. CANINE ATOPIC DERMATITIS MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 26. CANINE ATOPIC DERMATITIS MARKET SHARE, BY KEY PLAYER, 2023

Companies Mentioned

  • AB Science SA
  • AbbVie, Inc.
  • Agrolabo SpA
  • Bimeda, Inc.
  • Bioceltix JSC
  • Bioiberica S.A.U.
  • Boehringer Ingelheim International GmbH
  • Ceva Santé Animale
  • Dechra Pharmaceuticals PLC
  • Deep Marine Collagen
  • Elanco Animal Health Incorporated
  • Farnam Companies, Inc.
  • IDEXX Laboratories, Inc.
  • Incyte Corporation
  • Kemin Industries, Inc.
  • LEO Pharma A/S
  • Merck & Co. Inc.
  • Natural Dog Company
  • Nextmune
  • Nippon Zenyaku Kogyo Co., Ltd.
  • Novartis AG
  • Ourofino Animal Health
  • Pfizer Inc
  • Phibro Animal Health Corporation
  • Regeneron Pharmaceuticals, Inc
  • Saiba Animal Health AG
  • Toray Industries Inc.
  • Vetoquinol S.A.
  • Virbac Corporation
  • Zinpro Corporation
  • Zoetis Inc.
  • Zymox by Pet King Brands LLC

Methodology

Loading
LOADING...

Table Information